Abstract
The landscape of systemic therapies available for treating BrM has recently expanded to include new HER2-targeted tyrosine kinase inhibitors and antibody-drug conjugates for patients with HER2-positive metastatic breast cancer (MBC). Given that HER2-targeted therapies are now being investigated among patients whose disease does not meet established cut points for HER2 expression, we examined the proportion of patients with “HER2-low” in breast cancer brain metastases BrM.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
